Rocket One opened lower at $0.36, compared with its previous close of $0.37. In the last trading session, the stock traded between $0.35 and $0.37. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Rocket One is now worth
$ 1.33
Resulting in a loss of
$ 98.67 (98.67%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.03 (-7.01%)
Day High
$0.37
Day Low
$0.35
Day Open
$0.36
Prev Close
$0.37
Volume
1,40,740
1W Return
-20.69%
1M Return
-42.40%
3M Return
-56.38%
6M Return
-47.74%
1Y Return
-73.05%
Fundamentals
Market Cap ($ Mn)
9
PE Ratio
-
PB Ratio
2.02
PEG Ratio
-
ROE
-146.54%
ROCE
-146.53%
EPS (TTM)
$-0.17
Investment Returns
1 Week
-20.69%
1 Month
-42.40%
3 Months
-56.38%
6 Months
-47.74%
9 Months
-62.98%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
Rocket One subsidiary Tracer Drone secures public safety wins across 8 agencies
Rocket One Inc.'s subsidiary Tracer Drone Technologies secured wins across eight public safety agencies. The engagements include four law enforcement agencies, two sheriff's departments, and two fire departments. Services provided range from FAA Part 107 pilot certification preparation to turnkey Drone as First Responder systems. The wins follow the recent acquisition of Tracer Drone by Rocket One, demonstrating immediate operational integration.
Yesterday
3Nov
Hoth Therapeutics ends Phase 2a trial of HT-001 on strong interim data
Hoth Therapeutics ended its Phase 2a clinical trial of HT-001 early due to strong interim efficacy results. The subsidiary plans to seek FDA feedback for advancing HT-001 into a potential Phase 3 clinical program. Rocket One Inc. announced the decision through its biotechnology subsidiary, Hoth Therapeutics.
